Biotest AG: Biotest confirms good tolerability and efficacy of Intratect(R) in primary and secondary immunodeficiencies in an observational study
DGAP-News: Biotest AG
/ Key word(s): Study
Biotest confirms good tolerability and efficacy of Intratect(R) in primary and secondary immunodeficiencies in an observational study
- Proven reduction of infections in patients with secondary antibody deficiency
- Enhanced quality of life during treatment
- Good tolerability allows reduction of pre-medication
Dreieich, 22 April 2021. Intratect(R) is a human intravenous immunoglobulin that is manufactured and marketed by Biotest in two concentrations (50 g/l and 100 g/l).
Patient data were collected in Germany in a large observational study focusing on patients with acquired antibody deficiency, e.g., due to chemotherapy. Up to the time of the interim analysis, 488 patients had been included. The age range was 16-91 years with a treatment duration of up to 2,225 days. The indications for immunoglobulin therapy were primary (32%) and secondary (61%) immunodeficiency, immune thrombocytopenia (4%) and other diseases (3%).
The attending physicians reported very good efficacy and satisfaction for over 92% of the patients. Patient satisfaction and quality of life increased over time during treatment with Intratect.
In clinical practice, it was noticeable that the immunoglobulin levels were increased in most patients (> 4 g/l) despite a relatively low dose of immunoglobulin (median 0.2 g/kg). Also, a considerable percentage of patients with a secondary immunodeficiency experienced an infection because they had been given a lower dosage than recommended in the guidelines. Dosage according to the guidelines presumably prevents further infections. Prior to the first administration of immunoglobulin in the study, 32% of the patients received pre-medication; after one year of Intratect treatment, this percentage was reduced by half to 16%.
The study thus underlines the good tolerability and efficacy of Intratect(R), leading to an improvement in the patients' quality of life.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
22.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1187292|
|End of News||DGAP News Service|